La cadena de opciones muestra datos clave de las opciones de acciones de Addex Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Addex Therapeutics..

Addex Therapeutics (NASDAQ:ADXN) Bolsa, Cadena de Opciones

Addex Therapeutics

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

ADXN

BYND

CELC

CIIT

DCTH

DGXX

EXEL

FBGL

FCUV

FPAY

NCNA

OLMA

RANI

RAPT

TGHL

VIVK

XRTX

YGMZ

DCTH impulsa el premercado con resultados clínicos positivos del estudio CHOPIN, mientras Beyond Meat y Celcuity lideran las mayores subidas.

Acciones de Delcath Systems (DCTH) suben un 14%; Aquí están 20 acciones que se mueven en el premercado

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics Ltd

Press Releases

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Addex Convenes Annual General Meeting 2025

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Appoints Bank of New York Mellon as Depositary Bank

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Biofrontera

Cocrystal Pharma

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

IM Cannabis

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

ProPhase Labs

Pulmatrix

Q/C Technologies

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TherapeuticsMD

VYNE Therapeutics

cbdMD

HC Wainwright & Co.

Comments

Addex Therapeutics

Addex Therapeutics (ADXN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL